uniQure

$32.95
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.80 (-5.18%) Today

$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell uniQure and other stocks, options, and ETFs commission-free!

About QURE

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands. The listed name for QURE is uniQure N.V. Ordinary Shares.

CEO

Matthew C. Kapusta

Employees

248

Headquarters

Amsterdam, Noord-Holland

Founded

1998

Market Cap

1.50B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

576.79K

High Today

$35.50

Low Today

$32.75

Open Price

$34.93

Volume

678.13K

52 Week High

$71.45

52 Week Low

$32.75

QURE News

BenzingaMar 1

uniQure Announces 2020 Financial Results and Highlights Recent Company Progress

~ Six patient procedures now completed in Phase I/II for Huntington's disease, including two procedures conducted in February 2021, with full enrollment of firs

Analyst Ratings

88%

of 17 ratings

Buy

88%

Hold

12%

Sell

QURE Earnings

-$1.21

-$0.81

-$0.40

$0.00

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

-$0.01 per share